Founder and CEO, Burrill & Company, San Francisco, CA
G. Steven Burrill has served as a member of our board of directors since August 2004, and as Chairman of the Board since November 2004. Mr. Burrill is the founder and CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Prior to founding Burrill & Company in 1994, Mr. Burrill spent 27 years with Ernst & Young, directing and coordinating the firm's services to clients in the life sciences, high technology and manufacturing industries worldwide. Mr. Burrill currently serves as a member of the board of directors of DepoMed, Inc., a public biotechnology company, where he is a member of the audit committee and a member of the compensation committee and a board director at Targacept, Inc. Mr. Burrill is a member of the board of directors of Catalyst Biosciences, Inc., Phytomedics, Inc. Intranasal Therapeutics, Proteogenix, XDx (Expression Diagnostics), Bioimagine (Chairman), all privately held biotechnology companies. Mr. Burrill received his B.B.A. from the University of Wisconsin-Madison.
Professor, Emory University School of Law, Atlanta, GA
William J. Carney, Esq. has served as a member of our board of directors since November 2000. Mr. Carney is a professor of corporate law at Emory University in Atlanta, Georgia. Prior to joining the Emory University faculty in 1978, Professor Carney was a professor of law at the University of Wyoming and a partner in the Denver law firm of Holland & Hart. He has been a visiting professor at several prestigious United States and international law schools. Professor Carney has served as chair of the Corporate Code Revision Committee and as a member of the Executive Committee of the Corporate Section of the State Bar of Georgia. He is the author of two leading casebooks on mergers and acquisitions and corporate finance, and more than 50 articles and book chapters on related topics. Professor Carney received his B.A. and L.L.B. from Yale University.
Former President, Roche Pharmaceuticals Division, New Jersey
Herbert J. Conrad has served as a member of our board of directors and the Nominating and Corporate Governance Committee since March 2008. Mr. Conrad is currently the Chairman of the Board of Directors of Sapphire Therapeutics, a Director of Savient Pharmaceuticals, Celldex and Symphony Evolution, and serves on the Medical Advisory Board of Henry Schein. From 1960 to 1993, Mr. Conrad served in a variety of marketing and strategic planning roles at Hoffmann LaRoche, and he was the President of the Roche Pharmaceuticals Division and a Member of the Executive Committee and Board of Directors from 1982 through 1993. Mr. Conrad has been involved in a number of business, industry, academic, civic and philanthropic organizations, and he also served in the U.S. Army's Medical Services Corps. Mr. Conrad earned his undergraduate and graduate degrees in Pharmacy from the Brooklyn College of Pharmacy. He also has received a Doctorate in Humane Letters (Honorary) from Long Island University.
Elliot F. Hahn , Ph.D. has been a member of our board of directors since August 2000. Dr. Hahn has served as the president of ACCU-BREAK Pharmaceuticals, Inc. since October 2004. Dr. Hahn was a co-founder of Andrx Corporation and has served as Chairman Emeritus since March 2003. Dr. Hahn served as Andrx Corporation's President from February 1993 until March 2003, Chief Executive Officer from October 2001 until June 2002, and as Chairman of the Board of Directors from June 2002 through March 2003. From June 1990 until February 1993, Dr. Hahn was Vice President for Scientific Affairs of IVAX, where he was involved in the evaluation and licensing of product opportunities and was responsible for maintaining IVAX's intellectual property. Prior to that, he was Vice President of Research at the pharmaceutical subsidiary of IVAX. Before joining IVAX, Dr. Hahn was an associate professor at The Rockefeller University, an assistant professor at Albert Einstein College of Medicine, and a member of the Institute for Steroid Research at Montefiore Hospital, all in New York City. Since 1988, he has been an adjunct Associate Professor at the University of Miami School of Medicine. He has authored or co-authored over sixty peer-reviewed scientific publications. Dr. Hahn serves as a member of the board of directors of Nations Health, CyDex, Inc. and a number of privately held pharmaceutical companies. Dr. Hahn holds a B.S. with Honors in Chemistry from City College of New York and a Ph.D. in Organic Chemistry from Cornell University.
Michael K. Inouye has been a member of our board of directors since June 2005. Mr. Inouye recently served as Senior Vice President of Corporate and Commercial Development of Pharmacyclics, Inc. from May 2007 to February 2008 and is currently an independent industry consultant. From March 2006 through February 2007, Mr. Inouye was Senior Vice President, Commercial Operations of Telik, Inc. From May 2005 through February 2006, Mr. Inouye was working as an independent pharmaceutical industry consultant. Mr. Inouye was a worldwide commercial operations executive at Gilead Sciences from August 1995 to April 2005 where he led the global product launches of Viread and Emtriva, two leading HIV therapeutics sold both alone and in combination as Truvada, and Hepsera, for HBV. Prior to joining Gilead Sciences, Mr. Inouye served in sales and marketing and business development roles at Merck & Co. and American Home Products. Mr. Inouye received a B.S. in Food & Science Technology from the University of California at Davis and an M.B.A. from California State Polytechnic University, Pomona.
Fredric Price has served as a member of our board since March 2007. He is Executive Chairman of the board of Directors of Peptimmune, Chairman of the board of Directors and CEO of Chiasma, a member of the board of directors of Enobia Pharma, and a member of the board of Directors of Pharmasset. In May 2008, he stepped down after 4 years as Chairman of the Board of Omrix Biopharmaceuticals. Previously, he was Chairman of the board of irectors and Chief Executive Officer of BioMarin Pharmaceutical. As Chairman and/or CEO, he has raised $500 million in a variety of securities transactions, led a total of 17 M&A and licensing transactions, built FDA approved facilities and had drugs approved in the US as well as in international markets. His earlier experience includes having been President, Chief Executive Officer and a member of the board of directors of Applied Microbiology, Vice President of Finance and Administration and Chief Financial Officer of Regeneron Pharmaceuticals, the founder of the strategy consulting firm RxFDP, and Vice President of Pfizer Pharmaceuticals with both line and staff responsibilities. Mr. Price is a co-inventor of 12 issued U.S. patents and one U.S. patent application. He received a B.A. from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.
P. Schaefer Price is a member of our board of directors and is our President and Chief Executive Officer and has been with Pharmasset since June 2004. From September 2002 to June 2004, Mr. Price served as an Executive in Residence at Bay City Capital, a venture capital firm for which he provided advice to portfolio companies and assisted with due diligence for investment opportunities. From July 2001 until September 2002, Mr. Price served as Managing Director of Lakeshore Bioventures, a lifescience merchant bank. From January 1997 until July 2001, Mr. Price was the President of PowderJect Vaccines, the vaccine subsidiary of PowderJect Pharmaceuticals PLC. Under his leadership, PowderJect's vaccine business grew from a small research group into the world's sixth largest vaccine company prior to its acquisition by Chiron Corporation. Mr. Price has also served as a Vice President at the merchant bank of Burrill & Craves and Assistant to the President at Berlex Biosciences. Mr. Price received a B.S. in Molecular Biology from the University of Wisconsin—Madison and an M.B.A. from the University of Minnesota.
Robert F. Williamson III
Life Sciences Consultant, Piedmont, CA
Robert F. Williamson III has served as a member of our board of directors since August 2004. Mr. Williamson is currently a consultant to life sciences companies. Mr. Williamson is Executive Chairman of Strategic Enzyme Applications (SEA) and was the Chief Executive Officer and a director of Arriva Pharmaceuticals from April 2004 to May 2006. He is also the founder of LaSalle Venture Advisors, a consulting firm, where he has served as a consultant since 2002. From 2002 until 2004, Mr. Williamson served as the President and Chief Operating Officer of Eos Biotechnology. Mr. Williamson also served as the President and Chief Operating Officer of DoubleTwist, Inc., a genomics platform company, from July 1999 until February 2002 . Mr. Williamson was also a partner with the Boston Consulting Group, Inc. from 1991 through 1999, where his clients included top global pharmaceutical and medical device companies. Mr. Williamson received a B.A. in Economics from Pomona College and an M.B.A. from the Stanford Graduate School of Business.
show all
hide all
